Exact Sciences Q1 2020 Earnings Report
Key Takeaways
Exact Sciences Corp. reported revenue of $347.8 million for the first quarter ended March 31, 2020, compared to $162.0 million for the same period of 2019. The company's screening revenue was $219.5 million, an increase of 35 percent, while precision oncology revenue was $128.4 million. The net loss was $105.7 million, or $0.71 per share.
Total revenue was $347.8 million, compared to $162.0 million.
Screening revenue was $219.5 million, an increase of 35 percent.
Precision Oncology revenue was $128.4 million.
Net loss was $105.7 million, or $0.71 per share.
Exact Sciences
Exact Sciences
Exact Sciences Revenue by Segment
Forward Guidance
Exact Sciences plans to play an even greater role in cancer screening and guiding therapy decisions after the coronavirus pandemic abates.
Revenue & Expenses
Visualization of income flow from segment revenue to net income